POSTDOC POSITION IN CANCER RESEARCH IN BERLIN AVAILABLE in the lab of Prof. Clemens Schmitt working on
Genetic Mechanisms of Oncogene- and Therapy-Induced Senescence in vivo
We are interested in genetic programs and mutations which impact on tumor development and sensitivity to anticancer therapies. Utilizing transgenic mouse models, we generate primary lymphomas with defined genetic lesions (by intercrossing cancer-prone transgenics to knockout mice, and by retroviral gene transfer into established lymphoma cells or hematopoietic stem cells). These tumors are transplantable and undergo anticancer treatment at their natural sites. Using this tractable system, which recapitulates typical features of human Non-Hodgkin’s lymphomas, we study genetic and biochemical effects of oncogenic action and drug responses in vivo by combining various “-omics” technologies (genome/transcriptome, proteome, kinome, metabolome) with functional, mechanism-driven studies.
We are particularly interested in the contribution of cell-autonomous and environmental components (including the host immune response) in drug-induced apoptosis and premature senescence to chemoresistance, and further focus on stemness and cellular plasticity/transdifferentiation in senescence. Our translational aims are to elucidate molecular mechanisms of cellular senescence and drug resistance in order to develop conceptually novel targeted therapies.
We are interested in genetic programs and mutations which impact on tumor development and sensitivity to anticancer therapies. Utilizing transgenic mouse models, we generate primary lymphomas with defined genetic lesions (by intercrossing cancer-prone transgenics to knockout mice, and by retroviral gene transfer into established lymphoma cells or hematopoietic stem cells). These tumors are transplantable and undergo anticancer treatment at their natural sites. Using this tractable system, which recapitulates typical features of human Non-Hodgkin’s lymphomas, we study genetic and biochemical effects of oncogenic action and drug responses in vivo by combining various “-omics” technologies (genome/transcriptome, proteome, kinome, metabolome) with functional, mechanism-driven studies.
We are particularly interested in the contribution of cell-autonomous and environmental components (including the host immune response) in drug-induced apoptosis and premature senescence to chemoresistance, and further focus on stemness and cellular plasticity/transdifferentiation in senescence. Our translational aims are to elucidate molecular mechanisms of cellular senescence and drug resistance in order to develop conceptually novel targeted therapies.
For information in greater detail please see, for example, Schmitt-CA et
al., Nature Med. (2000), Schmitt-CA et al., Cancer Cell (2002),
Schmitt-CA et al., Cell (2002), Braig-M et al., Nature (2005),
Bouchard-C et al., Genes Dev. (2007), Reimann-M et al., Cancer Cell
(2010), and Jing-H et al., Genes Dev. (2011); furthermore, see
Schmitt-CA, Biochimica et Biophysica Acta (2007), for an overview. This
study group is embedded in a combined clinical and basic research
campus, since its group leader is affiliated with both the Department of
Hematology-Oncology at Charité-Virchow Campus (Humboldt-University) and
the distinguished Max-Delbrück-Center for Molecular Medicine in Berlin.
Moreover, we are partner in a large lymphoma-related transregional
collaborative research center (SFB/TRR54), which is an excellent network
for scientific interaction and technology transfer. Berlin is the
scientific place to work, provides a very international environment and
high life quality, and is!
one of the most vibrant cities in Europe.
REQUIREMENTS
Join our highly-motivated team if you are interested in creative approaches and novel strategies to dissect the pathways of stress-inducible cellular senescence and chemoresistance in vivo. You hold a Ph.D. or equivalent, and you are familiar with all basic techniques in molecular biology, biochemistry and histology (i.e. cloning, analyses of proteins and DNA/RNA, cell culture, and immunohistochemistry). Expertise in any of the following is preferred: genome-wide screens, RNA interference, retroviral/lentiviral vector design, inducible gene expression systems, proteomics/metabolomics, cellular bioenergetics, molecular, cellular or organismic imaging, or generation of transgenics/knockout mice. Lab communication is in English. Please send your CV including a list of publications and two references/letters of recommendation to
Prof. Dr. Clemens A. Schmitt, M.D.
Max-Delbrück-Center for Molecular Medicine and
Charité/Campus Virchow/Hematology-Oncology
Augustenburger Platz 1
D-13353 Berlin
Germany
e-mail clemens.schmitt@charite.de
one of the most vibrant cities in Europe.
REQUIREMENTS
Join our highly-motivated team if you are interested in creative approaches and novel strategies to dissect the pathways of stress-inducible cellular senescence and chemoresistance in vivo. You hold a Ph.D. or equivalent, and you are familiar with all basic techniques in molecular biology, biochemistry and histology (i.e. cloning, analyses of proteins and DNA/RNA, cell culture, and immunohistochemistry). Expertise in any of the following is preferred: genome-wide screens, RNA interference, retroviral/lentiviral vector design, inducible gene expression systems, proteomics/metabolomics, cellular bioenergetics, molecular, cellular or organismic imaging, or generation of transgenics/knockout mice. Lab communication is in English. Please send your CV including a list of publications and two references/letters of recommendation to
Prof. Dr. Clemens A. Schmitt, M.D.
Max-Delbrück-Center for Molecular Medicine and
Charité/Campus Virchow/Hematology-Oncology
Augustenburger Platz 1
D-13353 Berlin
Germany
e-mail clemens.schmitt@charite.de
No comments:
Post a Comment